Rituximab sensitizes TRAIL-resistant B-NHL lines to apoptosis by both TRAIL and fully humanized antibodies targeting TRAIL-RI (mapatumumab) and TRAIL-R2 (lexatumumab)

被引：0
|
作者：
Vega, Mario I. [1 ,2 ]
Haerta-Yepez, Sara [2 ,3 ]
Baritaki, Stavroula [2 ]
Martinez-Paniagua, Melisa A. [1 ]
Gonzalez-Bonilla, Cesar R. [1 ]
Bonavida, Benjamin [2 ]
机构：
[1] CML La Raza, IMSS, Unit Invest Immunol Infect, Mexico City, DF, Mexico
[2] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA
[3] Hosp Infantil Mexico Dr Federico Gomez, Unit Invest Enfermedades Oncol, Mexico City, DF, Mexico
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2350
引用
收藏
页码：695A / 695A
页数：1
相关论文
共 12 条
  • [1] Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody resistant NSCLC cell lines when treated in combination with bortezomib
    Luster, Troy
    Carrell, Jeffrey
    Humphreys, Robin
    CANCER RESEARCH, 2009, 69
  • [2] Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
    Luster, Troy A.
    Carrel, Jeffrey A.
    McCormick, Kathy
    Sun, David
    Humphreys, Robin
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (02) : 292 - 302
  • [3] Diclofenac sensitizes melanoma cells to TRAIL-induced apoptosis through upregulation of TRAIL-R2/DR5 in the resistant melanoma cells
    Strauss, M. Vazquez
    Stingl, G.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 : S92 - S92
  • [4] Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor - Related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2
    Smith, Mitchell R.
    Jin, Fang
    Joshi, Indira
    CLINICAL CANCER RESEARCH, 2007, 13 (18) : 5528S - 5534S
  • [5] Bortezomib sensitizes non-Hodgkin's lymphoma (NHL) cells to apoptosis induced by antibodies to trail receptors TRAIL-R1 and-R2
    Joshi, I.
    Jin, F.
    Smith, M. R.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2006, 21 (04) : 390 - 391
  • [6] Triggering of TRAIL-R1 and TRAIL-R2 death receptors by their selective fully human agonistic antibodies induces apoptosis in primary and cultured lymphoma cells
    Georgakis, G
    Li, Y
    Humphreys, R
    Andreeff, M
    O'Brien, S
    Younes, M
    Carbone, A
    Albert, V
    Younes, A
    ANNALS OF ONCOLOGY, 2005, 16 : 70 - 70
  • [7] Sensitization of rituximab-sensitive and rituximab-resistant B-NHL cell lines/clones to TRAIL-induced apoptosis by bortezomib and NF-κB inhibitors.
    Jazirehi, AR
    Bonavida, B
    BLOOD, 2005, 106 (11) : 435A - 436A
  • [8] Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death
    Georgakis, GV
    Li, Y
    Humphreys, R
    Andreeff, M
    O'Brien, S
    Younes, M
    Carbone, A
    Albert, V
    Younes, A
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (04) : 501 - 510
  • [9] Rituximab-mediated sensitization of B-NHL cells lines to TRAIL-Induced apoptosis: Involvement of YY1 suppression and DR5 upregulation.
    Vega, Mario I.
    Huerta-Yepez, Sara
    Baritaki, Stavroula
    Bonilla-Gonzalez, Cesar
    Bonavida, Benjamin
    BLOOD, 2006, 108 (11) : 676A - 676A
  • [10] DNMT1 and DNMT3b silencing sensitizes human hepatoma cells to TRAIL-mediated apoptosis via up-regulation of TRAIL-R2/DR5 and caspase-8
    Kurita, Satoshi
    Higuchi, Hajime
    Saito, Yoshimasa
    Nakamoto, Nobuhiro
    Takaishi, Hiromasa
    Tada, Shinichiro
    Saito, Hidetsugu
    Gores, Gregory J.
    Hibi, Toshifumi
    CANCER SCIENCE, 2010, 101 (06): : 1431 - 1439
12